Compare Atmos Energy Corporation (ATO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs ResMed Inc. — how do they compare? Atmos Energy Corporation trades at $168.97 (market cap $28.59B), while ResMed Inc. trades at $224.06 (market cap $32.61B). The key difference: Atmos Energy Corporation and ResMed Inc. are close in size by market cap, and Atmos Energy Corporation pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| ATO | RMD | |
|---|---|---|
Market Cap | $28.59B | $32.61B |
Sector | Utilities | Health |
52-Week High | $192.25 | $293.73 |
52-Week Low | $162.44 | $182.82 |
Enterprise Value | $38.40B | $31.97B |
Dividend Yield | 2.36% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $167.92, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company reported Q3 2026 EPS of $1.43, beating estimates of $1.35, with revenue growth of 4.8% year-over-year. Strong profitability metrics include a 28.5% net income margin and 62.2% gross margin, while valuation ratios show a P/E of 20.2 and P/S of 5.7. Recent corporate developments include board appointments and dividend declarations of $1.00 per share.
ATO presents a mixed outlook with solid fundamentals and analyst support but faces technical headwinds. The consensus price target of $190.57 suggests 13.5% upside potential, supported by 45% buy ratings. Risks include high capital expenditures impacting cash flow and debt levels near $7.9 billion. Earnings growth and rate approvals provide catalysts, though the stock's bearish technical trend warrants caution near-term.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
